Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.

Extracellular proteolysis by the plasminogen/plasmin (Plg/plasmin) system and MMPs is required for tissue injury in autoimmune and inflammatory diseases. We demonstrate that a Plg cascade synergizes with MMP-9/gelatinase B in vivo during dermal-epidermal separation in an experimental model of bullous pemphigoid (BP), an autoimmune disease. BP was induced in mice by antibodies to the hemidesmosomal antigen BP180. Mice deficient in MMP-9 were resistant to experimental BP, while mice deficient in Plg and both tissue Plg activator (tPA) and urokinase Plg activator (uPA) showed delayed and less intense blister formation induced by antibodies to BP180. Plg-deficient mice reconstituted locally with Plg or the active form of MMP-9 (actMMP-9), but not the proenzyme form of MMP-9 (proMMP-9), developed BP. In contrast, proMMP-9 or actMMP-9, but not Plg, reconstituted susceptibility of MMP-9-deficient mice to the skin disease. In addition, MMP-3-deficient mice injected with pathogenic IgG developed the same degree of BP and expressed levels of actMMP-9 in the skin similar to those of WT controls. Thus, the Plg/plasmin system is epistatic to MMP-9 activation and subsequent dermal-epidermal separation in BP.

[1]  E. Bröcker,et al.  Granulocyte‐derived elastase and gelatinase B are required for dermal–epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid , 2004, The Journal of pathology.

[2]  S. Tsirka,et al.  Involvement of Tissue Plasminogen Activator in Onset and Effector Phases of Experimental Allergic Encephalomyelitis , 2002, The Journal of Neuroscience.

[3]  M. Polette,et al.  Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. , 2001, The Journal of investigative dermatology.

[4]  M. G. Fleming,et al.  Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. , 2001, The Journal of clinical investigation.

[5]  P. Carmeliet,et al.  Tissue-Type Plasminogen Activator Deficiency Exacerbates Arthritis1 , 2001, The Journal of Immunology.

[6]  T. Bugge,et al.  Plasminogen activators direct reorganization of the liver lobule after acute injury. , 2001, The American journal of pathology.

[7]  S. Maxwell,et al.  Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. , 2001, Journal of cell science.

[8]  Z. Werb,et al.  The Serpin α1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 In Vivo , 2000, Cell.

[9]  T. Bugge,et al.  Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice. , 2000, Methods.

[10]  P. Carmeliet,et al.  Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. , 2000, The American journal of pathology.

[11]  D. Witte,et al.  Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Nielsen,et al.  Functional overlap between two classes of matrix‐degrading proteases in wound healing , 1999, The EMBO journal.

[13]  D. Collen The Plasminogen (Fibrinolytic) System , 1999, Thrombosis and Haemostasis.

[14]  H. Lijnen,et al.  Matrix Metalloproteinase System Deficiencies and Matrix Degradation , 1999, Thrombosis and Haemostasis.

[15]  J. Sipley,et al.  Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.

[16]  Z. Werb,et al.  Gelatinase B–deficient Mice Are Resistant to Experimental Bullous Pemphigoid , 1998, The Journal of experimental medicine.

[17]  P. Carmeliet,et al.  Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[18]  R. Nagle,et al.  Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin. , 1998, The Biochemical journal.

[19]  Gabriele Bergers,et al.  MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.

[20]  T. Bugge,et al.  Ligneous conjunctivitis in plasminogen-deficient mice. , 1998, Blood.

[21]  Z. Werb ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.

[22]  K. Fang,et al.  Dog Mast Cell α-Chymase Activates Progelatinase B by Cleaving the Phe88-Gln89 and Phe91-Glu92 Bonds of the Catalytic Domain* , 1997, The Journal of Biological Chemistry.

[23]  W. Kao,et al.  Healing of corneal epithelial defects in plasminogen- and fibrinogen-deficient mice. , 1997, Investigative ophthalmology & visual science.

[24]  D. Witte,et al.  Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. , 1997, Blood.

[25]  C. López-Otín,et al.  Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). , 1997, European journal of biochemistry.

[26]  G. Till,et al.  A major role for neutrophils in experimental bullous pemphigoid. , 1997, The Journal of clinical investigation.

[27]  L. Zanetta,et al.  Control of type IV collagenase activity by components of the urokinase–plasmin system: a regulatory mechanism with cell‐bound reactants , 1997, The EMBO journal.

[28]  P. Carmeliet,et al.  Plasminogen and Plasminogen Activators Protect against Renal Injury in Crescentic Glomerulonephritis , 1997, The Journal of experimental medicine.

[29]  P. M. Wilson,et al.  Changes in rat corneal matrix metalloproteinases and serine proteinases under vitamin A deficiency. , 1997, Current eye research.

[30]  W. Nauseef,et al.  Isolation and Functional Analysis of Neutrophils , 1996, Current protocols in immunology.

[31]  P. Carmeliet,et al.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  L. Lund,et al.  Impaired wound healing in mice with a disrupted plasminogen gene , 1996, Nature Medicine.

[33]  S. E. Brodie New York, New York, USA , 1996 .

[34]  R. Fridman,et al.  Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). , 1995, Cancer research.

[35]  T. Bugge,et al.  Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. , 1995, Genes & development.

[36]  G. Till,et al.  The role of complement in experimental bullous pemphigoid. , 1995, The Journal of clinical investigation.

[37]  K. Imai,et al.  Matrix Metalloproteinase 7 (Matrilysin) from Human Rectal Carcinoma Cells , 1995, The Journal of Biological Chemistry.

[38]  W. Parks,et al.  92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. , 1994, The Journal of clinical investigation.

[39]  P. Carmeliet,et al.  Physiological consequences of loss of plasminogen activator gene function in mice , 1994, Nature.

[40]  C. Soria,et al.  Activation of the 92 kDa type IV collagenase by tissue kallikrein , 1993, Journal of cellular physiology.

[41]  J. Troy,et al.  A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. , 1993, The Journal of clinical investigation.

[42]  M. Kramer,et al.  The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin. , 1993, The Journal of clinical investigation.

[43]  F. Wojnarowska,et al.  An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid , 1993, Clinical and experimental dermatology.

[44]  J. Reynolds,et al.  The Role of Plasmhogen Activators in the Regulation of Connective Tissue Metalloproteinases a , 1992 .

[45]  K. Naka,et al.  Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. , 1992, The Journal of biological chemistry.

[46]  L. Diaz,et al.  Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. , 1992, The Journal of investigative dermatology.

[47]  M. Kramer,et al.  Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid , 1992, The British journal of dermatology.

[48]  A. Strongin,et al.  Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. , 1992, The Journal of biological chemistry.

[49]  J. Enghild,et al.  Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. , 1992, The Journal of biological chemistry.

[50]  J. Uitto,et al.  Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. , 1991, The Journal of biological chemistry.

[51]  D. Parry,et al.  Comparison of molecularly cloned bullous pemphigoid antigen to desmoplakin I confirms that they define a new family of cell adhesion junction plaque proteins. , 1991, The Journal of biological chemistry.

[52]  D. Belin,et al.  mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. , 1990, The Journal of investigative dermatology.

[53]  W. Saunders,et al.  Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. , 1990, The Journal of clinical investigation.

[54]  S. Grando,et al.  Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. , 1989, Archives of dermatology.

[55]  P. Jensen,et al.  Epidermal plasminogen activator is abnormal in cutaneous lesions. , 1988, The Journal of investigative dermatology.

[56]  E. Bauer,et al.  Elevated levels of human collagenase inhibitor in blister fluids of diverse etiology. , 1986, The Journal of investigative dermatology.

[57]  S. Weiss,et al.  Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Uitto,et al.  Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid. , 1983, The Journal of investigative dermatology.

[59]  D. Priebat,et al.  Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. , 1982, The Journal of investigative dermatology.

[60]  M. Mihm,et al.  Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. , 1982, The Journal of investigative dermatology.

[61]  Z. Werb,et al.  Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. , 1977, The New England journal of medicine.

[62]  C. Orfanos,et al.  Electron microscopic study of bullous pemphigoid. , 1972, Archives of dermatology.

[63]  T. Brenn,et al.  Fitzpatrick’s Dermatology in General Medicine , 2007 .

[64]  J. Woessner,et al.  Matrix metalloproteinases and TIMPs , 2000 .

[65]  S. Shapiro,et al.  A critical role for neutrophil elastase in experimental bullous pemphigoid. , 2000, The Journal of clinical investigation.

[66]  P. Carmeliet,et al.  Role of plasminogen system components in focal cerebral ischemia , 1999 .

[67]  H. Kirschke,et al.  Chromogenic Peptide Substrates , 1999 .

[68]  K. Washington,et al.  Liver regeneration is transiently impaired in urokinase-deficient mice. , 1998, The American journal of physiology.

[69]  P. Carmeliet,et al.  Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. , 1998, Blood.

[70]  E. Coligan Current protocols in immunology , 1991 .

[71]  Gammon Wr Immune complex and complement-mediated leukocyte recruitment in bullous pemphigoid. , 1989 .

[72]  S. Grando,et al.  Cytotoxic proteases in blister fluid of pemphigus and pemphigoid patients. , 1989, International journal of tissue reactions.

[73]  P. Friberger Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. , 1982, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[74]  Thomas B. Fitzpatrick,et al.  Dermatology in general medicine , 1971 .